Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine Jeffrey A. SilvermanSteven R. Deitcher Review Article Open access 05 December 2012 Pages: 555 - 564
A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumors Elisabeth I. HeathJeffrey InfanteMohammed M. Dar Original Article 24 January 2013 Pages: 565 - 573
Characterization of the long-term pharmacokinetics of bevacizumab following last dose in patients with resected stage II and III carcinoma of the colon Jing LiManish GuptaDavid E. Allison Original Article 11 December 2012 Pages: 575 - 580
Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study Eric Van Den NesteBruno CazinClara Campàs Original Article Open access 11 December 2012 Pages: 581 - 591
The use of the 13C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels F. L. OpdamV. O. DezentjeH.-J. Guchelaar Original Article 11 December 2012 Pages: 593 - 601
Erratum to: The use of the 13C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels F. L. OpdamV. O. DezentjeH.-J. Guchelaar Erratum 12 January 2013 Pages: 603 - 603
Docetaxel plus cisplatin and bevacizumab for untreated patients with advanced/metastatic non-squamous non-small-cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group N. KentepozidisA. KotsakisV. Georgoulias Original Article 22 January 2013 Pages: 605 - 612
Capecitabine and oxaliplatin in combination as first- or second-line therapy for metastatic breast cancer: a Wisconsin Oncology Network trial U. O. NjiajuA. J. TevaarwerkJ. A. Stewart Original Article 11 December 2012 Pages: 613 - 618
Persistent chemoneuropathy in patients receiving the plant alkaloids paclitaxel and vincristine Jessica A. Boyette-DavisJuan P. CataPatrick M. Dougherty Original Article 11 December 2012 Pages: 619 - 626
A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies John F. DeekenRebecca SlackJohn L. Marshall Original Article 30 December 2012 Pages: 627 - 633
Potential role of acid ceramidase in conversion of cytostatic to cytotoxic end-point in pancreatic cancer cells Samy A. F. MoradMaria C. MessnerMyles C. Cabot Original Article 21 December 2012 Pages: 635 - 645
Phase I dose-escalation study of oral vinflunine administered once daily for 6 weeks every 8 weeks in patients with advanced/metastatic solid tumours J. P. DelordJ. M. TouraniA. Ravaud Original Article 09 January 2013 Pages: 647 - 656
Neoadjuvant chemotherapy using platinum- and taxane-based regimens for bulky stage Ib2 to IIb non-squamous cell carcinoma of the uterine cervix Tadahiro ShojiEriko TakatoriToru Sugiyama Original Article Open access 23 December 2012 Pages: 657 - 662
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience Robert L. FineAnthony P. GulatiJohn A. Chabot Original Article 31 January 2013 Pages: 663 - 670
Concomitant high gene copy number and protein overexpression of IGF1R and EGFR negatively affect disease-free survival of surgically resected non-small-cell-lung cancer patients V. LudoviniA. FlaccoL. Crinò Original Article 12 January 2013 Pages: 671 - 680
Population pharmacokinetics of cabazitaxel in patients with advanced solid tumors Géraldine M. FerronYang DaiDorothée Semiond Original Article Open access 09 January 2013 Pages: 681 - 692
Population pharmacokinetics of hyperthermic intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis after cytoreductive surgery Carlos Pérez-RuixoBelén ValenzuelaJuan José Pérez-Ruixo Original Article 30 December 2012 Pages: 693 - 704
Phase I/II study of amrubicin in combination with S-1 as second-line chemotherapy for non-small-cell lung cancer without EGFR mutation Shuji MurakamiFumihiro OshitaKouzo Yamada Original Article 18 January 2013 Pages: 705 - 711
(−)-Epigallocatechin-3-gallate inhibits human papillomavirus (HPV)-16 oncoprotein-induced angiogenesis in non-small cell lung cancer cells by targeting HIF-1α Li HeErying ZhangXudong Tang Original Article 06 January 2013 Pages: 713 - 725
Pharmacokinetics of docetaxel in gastric cancer patients with malignant ascites Hidenori TamegaiTeruo KaigaTadatoshi Takayama Original Article 12 January 2013 Pages: 727 - 731
XRCC1 and GSTP1 polymorphisms and prognosis of oxaliplatin-based chemotherapy in colorectal cancer: a meta-analysis Fanghui YeZhenfang LiuXiaobo Yang Original Article 09 January 2013 Pages: 733 - 740
Low dose capecitabine plus weekly paclitaxel in patients with metastatic breast cancer: a multicenter phase II study KBCSG-0609 Tetsuya TaguchiDaigo YamamotoKinki Breast Cancer Study Group (KBCSG) Original Article 20 January 2013 Pages: 741 - 747
Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years Nina E. KontnyGudrun WürthweinGeorg Hempel Original Article 13 January 2013 Pages: 749 - 763
Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial J. L. WelshB. A. WagnerJ. J. Cullen Original Article 05 February 2013 Pages: 765 - 775
p75NTR: an enhancer of fenretinide toxicity in neuroblastoma Veena GaneshanJohn AshtonNina F. Schor Original Article 13 January 2013 Pages: 777 - 787
A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker Masahiro HirakawaYasushi SatoJunji Kato Original Article 22 January 2013 Pages: 789 - 797
Immunogenicity and toxicity of transferrin receptor-targeted hybrid peptide as a potent anticancer agent Megumi KawamotoMasayuki KohnoKoji Kawakami Original Article 18 January 2013 Pages: 799 - 807
The hydroxyl epimer of doxorubicin controls the rate of formation of cytotoxic anthracycline-DNA adducts Robert A. ForrestLonnie P. SwiftSuzanne M. Cutts Short Communication 23 December 2012 Pages: 809 - 816
Investigating the role of nucleoside transporters in the resistance of colorectal cancer to 5-fluorouracil therapy Lee Cheng PhuaMainak MalHan Kiat Ho Short Communication 28 December 2012 Pages: 817 - 823
Immunohistochemical study of MRP5 expression in meningiomas George A. AlexiouAnn GoussiaAthanasios P. Kyritsis Short Communication 28 December 2012 Pages: 825 - 828